NasdaqGM - Nasdaq Real Time Price • USD
Gain Therapeutics, Inc. (GANX)
As of 3:23 PM EDT. Market Open.
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 3 |
Avg. Estimate | -0.29 | -0.29 | -1.19 | -1.13 |
Low Estimate | -0.39 | -0.42 | -1.6 | -1.59 |
High Estimate | -0.19 | -0.2 | -0.93 | -0.87 |
Year Ago EPS | -0.43 | -0.62 | -1.71 | -1.19 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 1 | 1 | 2 | 1 |
Avg. Estimate | 100k | 100k | 1.15M | 400k |
Low Estimate | 100k | 100k | 300k | 400k |
High Estimate | 100k | 100k | 2M | 400k |
Year Ago Sales | 55k | -- | 55k | 1.15M |
Sales Growth (year/est) | 81.80% | -- | 1,990.90% | -65.20% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.39 | -0.31 | -0.45 | -0.32 |
EPS Actual | -0.43 | -0.62 | -0.37 | -0.36 |
Difference | -0.04 | -0.31 | 0.08 | -0.04 |
Surprise % | -10.30% | -100.00% | 17.80% | -12.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.29 | -0.29 | -1.19 | -1.13 |
7 Days Ago | -0.29 | -0.29 | -1.19 | -1.13 |
30 Days Ago | -0.29 | -0.24 | -1.12 | -1.06 |
60 Days Ago | -0.29 | -0.24 | -1.12 | -1.06 |
90 Days Ago | -0.31 | -0.27 | -1.16 | -1.25 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | 3 | 2 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | GANX | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 32.60% | -- | -- | 0.80% |
Next Qtr. | 53.20% | -- | -- | 9.60% |
Current Year | 30.40% | -- | -- | 4.50% |
Next Year | 5.00% | -- | -- | 13.30% |
Next 5 Years (per annum) | -- | -- | -- | 11.09% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
Earnings
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/1/2024 |
Reiterates | Chardan Capital: Buy to Buy | 3/27/2024 |
Maintains | HC Wainwright & Co.: Buy to Buy | 12/4/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 9/18/2023 |
Initiated | Maxim Group: Buy | 9/12/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/31/2023 |
Related Tickers
COYA Coya Therapeutics, Inc.
8.16
-3.32%
GLSI Greenwich LifeSciences, Inc.
12.51
-2.95%
ANRO Alto Neuroscience, Inc.
13.30
-1.48%
OTLK Outlook Therapeutics, Inc.
8.04
-3.02%
CALC CalciMedica, Inc.
4.0100
-0.25%
RZLT Rezolute, Inc.
3.4535
+4.73%
TARA Protara Therapeutics, Inc.
2.6400
-4.00%
CUE Cue Biopharma, Inc.
1.5601
-1.26%
TRDA Entrada Therapeutics, Inc.
12.07
+1.34%
PCSA Processa Pharmaceuticals, Inc.
1.5895
+1.89%